APP下载
搜索
Cancer Drug Resistance
2019年2期
浏览往期
订阅
目录
Review
Drug resistance and combating drug resistance in cancer
Emerging targets in cancer drug resistance
Mechanism of resistance to immune checkpoint inhibitors
Molecular mechanisms of enzalutamide resistance in prostate cancer
New insights into acquired endocrine resistance of breast cancer
Overcome cancer drug resistance by targeting epigenetic modifications of centrosome
Pharmacogenetic and pharmacogenomic discovery strategies
Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
Pharmacogenetics of thiopurines
Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients
Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer
The epigenome in pediatric acute lymphoblastic leukemia:drug resistance and therapeutic opportunities
The role of histone lysine demethylases in cancer cells' resistance to tyrosine kinase inhibitors
Perspective
Perspective:plasticity,the enemy of the good
Opinion
Glutaminase inhibition in renal cell carcinoma therapy
Commentary
Resistance to ERK1/2 pathway inhibitors; sweet spots,fitness deficits and drug addiction
Daunorubicin can eliminate iPS-derived cancer stem cells via lCAD/CAD-independent DNA fragmentation